ClinicalTrials.gg
Active, not recruitingNCT06807463Updated Oct 9, 2026

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

A Phase 2 interventional study of TEV-53408 and Placebo in Celiac Disease, sponsored by Teva Branded Pharmaceutical Products R&D LLC. Active, not recruiting at 21 sites in 3 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Teva Branded Pharmaceutical Products R&D LLC (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Updated Oct 9, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Enrollment
33rd of 68
50 · median 46
Started
2025
with 4 others
Phase 2
21 of 103
1 open now
Primary completion
2026-10
later than 4 of 19 live
Registered
98th of 103
by date

Among the 103 studies in Celiac Disease with a site in United States, this one is the 33rd largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2025, is one of 21 in phase 2, reaches primary completion later than 4 of the 19 other live ones, and was the 98th registered.

Celiac Disease

352 studies on the registry are indexed under Celiac Disease; 77 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease.

The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease.

A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease.

The expected trial duration per participant is approximately 86 weeks.

03

Conditions studied

  • Celiac Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of celiac disease at least 12 months prior to screening
  • On a gluten-free diet for at least 12 months prior to screening
  • Women must not be pregnant, lactating, breastfeeding, or planning pregnancy during the trial period
  • Male participants (including vasectomized) with women of partners (whether pregnant or not) must use condoms and also agree not to donate sperm for the designated period

NOTE - Additional criteria apply, please contact the investigator for more information.

Exclusion criteria

Exclusion Criteria:

  • A diagnosis or suspicion of celiac disease
  • History of severe celiac-related symptoms following gluten exposure that require acute medical care or intervention of a health care professional
  • Any other gastrointestinal disease or condition that may interfere with the assessment of celiac disease
  • Current or history of or treatment of malignancy in the last 5 years, excluding treated basal cell carcinoma
  • Pregnant or lactating woman, or plans to become pregnant during the trial; any man who is considering fathering a child or donating sperm during the trial
  • A history of chronic alcohol or substance abuse disorder within the previous 2 years.
  • An active infection(s) requiring treatment with intravenous (iv) anti-infectives (antibiotics, antivirals, antifungals) within 30 days prior to screening or oral anti-infectives (antibiotics, antivirals, antifungals) within 14 days prior to screening
  • Received or intends to receive any within 4 weeks or any non-live vaccine 2 weeks prior to medicinal product administration.

NOTE- Additional criteria apply, please contact the investigator for more information

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    TEV-53408

    Drug: TEV-53408

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugTEV-53408

    Solution for subcutaneous (sc) injection

  • DrugPlacebo

    Solution for subcutaneous (sc) injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Villous Atrophy as Measured by Villous Height to Crypt Depth Ratio (Vh:Cd)

    Vh:Cd is used to assess the severity of celiac disease. It is calculated by dividing the villous height by the crypt depth. A lower ratio indicates more damage.

    Time frame: Baseline, Week 8

  2. Number of Participants With at Least One Treatment-Emergent Adverse Event

    Time frame: Up to Week 28

  3. Number of Participants With at Least One Treatment-Emergent Serious Adverse Event

    Time frame: Up to Week 28

  4. Number of Participants With at Least One Protocol-Defined Adverse Event of Special Interest (PDAESI)

    Time frame: Up to Week 28

  5. Number of Participants Who Discontinued From the Study Due to an Adverse Event

    Time frame: Up to Week 28

Secondary outcomes

  1. Change From Baseline in Intraepithelial Lymphocyte (IEL) Density

    Time frame: Baseline, Week 8

  2. Change From Baseline in the VCIEL score

    VCIEL score is a calculation using the standardized Vh:Cd and standardized IEL. The standardized Vh:Cd is calculated as the difference between the mean Vh:Cd subtracted from each Vh:Cd divided by the Vh:Cd standard deviation. The standardized IEL is calculated as the difference between the mean IEL subtracted from each IEL divided by the IEL standard deviation. VCIEL is the standardized Vh:Cd minus the standardized IEL.

    Time frame: Baseline, Week 8

07

Study locations

21 sites
  • Teva Investigational Site 12138
    Murrieta, California 92563, United States
  • Teva Investigational Site 12131
    Colorado Springs, Colorado 80907, United States
  • Teva Investigational Site 12134
    Inverness, Florida 34452, United States
  • Teva Investigational Site 12126
    Miami Lakes, Florida 33016, United States
  • Teva Investigational Site 12135
    New Port Richey, Florida 34653, United States
  • Teva Investigational Site 12130
    Atlanta, Georgia 30328, United States
  • Teva Investigational Site 12133
    Marrero, Louisiana 70072, United States
  • Teva Investigational Site 12132
    Clinton Township, Michigan 48038, United States
  • Teva Investigational Site 12121
    Wyoming, Michigan 49519, United States
  • Teva Investigational Site 12129
    Rochester, Minnesota 55905, United States
  • Teva Investigational Site 12128
    New York, New York 10032, United States
  • Teva Investigational Site 12125
    Greenville, North Carolina 27834, United States
  • Teva Investigational Site 12127
    Winston-Salem, North Carolina 27103, United States
  • Teva Investigational Site 12137
    Waco, Texas 76712, United States
  • Teva Investigational Site 12122
    Ogden, Utah 84405, United States
  • Teva Investigational Site 12123
    Lynchburg, Virginia 24502, United States
  • Teva Investigational Site 78139
    Fitzroy, 3065, Australia
  • Teva Investigational Site 78140
    Maroochydore, 4558, Australia
  • Teva Investigational Site 78137
    Midland, 6056, Australia
  • Teva Investigational Site 40063
    Helsinki, 00100, Finland
  • Teva Investigational Site 40062
    Tampere, 33520, Finland
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Oct 2026, 18 months.

Of 24 phase 2 interventional studies under Celiac Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's 18 months is close to that.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 4, 2025
StartActual
Mar 31, 2025
Primary completionActual
Oct 2, 2026was Sep 2026
CompletionEst.
Sep 14, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 15, 2026→Oct 2, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Sep 15, 2026→Oct 2, 2026 (now actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06807463
Responsible party
Sponsor
First posted
Feb 4, 2025
Start date
Mar 31, 2025
Primary completion
Oct 2, 2026
Completion
Sep 14, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion